CHEPLAPHARM Arzneimittel GmbH Sustainability Profile
CHEPLAPHARM Arzneimittel GmbH, a prominent player in the pharmaceutical industry, is headquartered in Greifswald, Germany. Founded in 1986, the company has established itself as a leader in the development, production, and distribution of high-quality generic and specialty pharmaceuticals. With a strong presence across Europe and expanding operations in various international markets, CHEPLAPHARM focuses on therapeutic areas such as oncology, cardiology, and neurology. The company is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to the evolving needs of healthcare providers and patients. Notable achievements include strategic partnerships and a robust pipeline of generics that enhance patient access to essential medications. CHEPLAPHARM's dedication to excellence positions it as a trusted name in the pharmaceutical landscape, continually striving to improve health outcomes worldwide.
DitchCarbon Score
How does CHEPLAPHARM Arzneimittel GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CHEPLAPHARM Arzneimittel GmbH's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CHEPLAPHARM Arzneimittel GmbH's reported carbon emissions
In 2023, CHEPLAPHARM Arzneimittel GmbH reported total emissions of approximately 146,900 kg CO2e, comprising 130,900 kg CO2e from Scope 1 and 16,000 kg CO2e from Scope 2 emissions. Notably, the company has made significant strides in reducing its carbon footprint, achieving a remarkable 92% reduction in Scope 2 emissions by switching its entire electricity consumption at its German sites to renewable energy sources. This initiative, implemented in 2023, underscores CHEPLAPHARM's commitment to environmental sustainability and transparency. In 2022, the company reported total emissions of approximately 182,000 kg CO2e, with Scope 1 emissions at 111,000 kg CO2e and Scope 2 emissions at 198,000 kg CO2e. The substantial reduction in Scope 2 emissions from the previous year highlights the effectiveness of their recent environmental measures. CHEPLAPHARM has not disclosed any Scope 3 emissions data, indicating a potential area for future focus. The company's climate commitments reflect a proactive approach to reducing its environmental impact, aligning with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | 323,000 | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is CHEPLAPHARM Arzneimittel GmbH's Industry?
How Carbon Intensive is CHEPLAPHARM Arzneimittel GmbH's Location?
CHEPLAPHARM Arzneimittel GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CHEPLAPHARM Arzneimittel GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
